GlassScriptPhysician profile
Sorin Vainer
NPI 1235152927
$1,963.06
in general payments reported to CMS, 2019-2025
19 companies · $189 in 2025
The $189 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $124 · 2021: $163 · 2022: $645 · 2023: $471 · 2024: $186 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $845.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $845.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $306.21 | 2022-2025 | |
| Horizon Therapeutics Plc | $254.59 | 2019-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $190.83 | 2019-2024 | Farxiga, Lokelma |
| Fresenius USA Marketing, INC. | $189.60 | 2019-2024 | Velphoro |
| Amgen INC. | $189.39 | 2019-2024 | Krystexxa |
| Vifor Pharma, INC. | $184.20 | 2019-2024 | |
| Akebia Therapeutics INC | $114.83 | 2020-2025 | Vafseo |
| Aurinia Pharma U.S., INC. | $88.05 | 2022 | |
| Calliditas Therapeutics US INC. | $79.10 | 2023-2024 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $78.76 | 2025 | |
| Travere Therapeutics, INC. | $50.29 | 2020-2025 | |
| Ardelyx, INC. | $49.92 | 2025 | Ibsrela |
| Otsuka America Pharmaceutical, INC. | $41.51 | 2022-2023 | Jynarque |
| Daiichi Sankyo INC. | $39.77 | 2022 | |
| Alnylam Pharmaceuticals INC. | $29.12 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.92 | 2024 | Jardiance |
| Lilly USA, LLC | $19.96 | 2023 | Jardiance |
| Glaxosmithkline, LLC. | $19.95 | 2023 | Benlysta |
| Abbvie INC. | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sorin Vainer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.